DOCKET NUMBER

APPLICATION NUMBER

REMARKS

Reconsideration is respectfully requested. Claims 1, 12, and 22 have been amended. New claims 33-41 have been added. Claims 1-41 will be pending after entry of these amendments.

Claims 1, 12, and 22 have been amended to indicate that the encoded polypeptide is "a cytochrome P450 which converts an active brassinosteroid to an inactive brassinosteroid." Support for this limitation may be found throughout the specification as filed. For example, in the Summary on page 5, lines 21-27, the specification indicates that "the *bas1* gene encodes a cytochrome P450 (CYP72B1) which has a role in brassinosteroid signaling or synthesis." The Summary further indicates that "[b]iochemical analysis indicates that CYP72B1 is a C-26 hydroxylase of brassinolide targeting it for inactivation."

New claims 33-41 have been added with this amendment. Support for the percent identity in claims 33, 34, 36, 37, 39 and 40 is found on page 13, lines 21-24 of the specification. Support for the hybridization wash conditions in claims 35, 38, and 41 is found on page 17, lines 5-13 of the specification.

Elections/Restrictions

Applicants acknowledge that the restriction requirement has been made final.

Information Disclosure Statement

Applicants thank the Examiner for considering the references submitted with the Information Disclosure Statement and returning the signed Form 1449. Applicants submit a Supplemental Information Disclosure Statement (SIDS) with the present response. Applicants respectfully request that the Examiner review and consider these references as well.

Telephonic Interview

Applicants thank Examiner Collins for the very helpful telephonic interview conducted on September 21, 2004. The state of the art as of filing of the priority application as it relates to the written description rejection and the enablement rejection was discussed at length. This response is submitted pursuant to that discussion.

Claim Objections